Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart attack drug may fix 'Hidden' vessel damage

NCT ID NCT06787430

Disease control Sponsor: China National Center for Cardiovascular Diseases Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether the drug nicorandil can improve blood flow in the heart's tiny vessels after a heart attack. About 170 patients having emergency angioplasty will receive either nicorandil or a placebo directly into their heart artery. The goal is to see if nicorandil reduces microvascular dysfunction, a common problem that can lead to worse outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
nicorandil
What this could lead to
If it works, this could point toward a simple, cheap way to improve blood flow in the heart's tiny vessels after a heart attack, potentially reducing long-term damage.
What could go wrong
This is a relatively small, early-phase trial testing a short-term drug effect. The benefit may be small or not translate to better long-term outcomes, and the drug can cause low blood pressure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 170 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Mar 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age between 18-80 * Diagnosis of STEMI and indicating for primary PCI * Diagnostic coronary angiography showed definite culprit vessel and primary PCI was planned to treat the culprit vessel. * Reference vessel diameter of culprit vessel was greater than 2.0 mm * There was no flow-limiting stenosis for the non-culprit vessels. * Understand the aim of this trial and agree to sign the informed consent form. Exclusion Criteria: * Acute in- stent thrombosis or in-stent stenosis lesions of culprit vessel. * Balloon angioplasty rather than stent was planned for the culprit vessel. * Allergic to nicorandil or systolic arterial pressure was less than 85mmHg before procedure * Vessel with twisted shape that was unable to be measured using AMR * Oral or intravenous use of nicorandil within one month. * Cardiac shock needing mechanical support. * Severely hepatic dysfunction. * Severely renal failure needing hemodialysis. * Contraindicated for coronary angiography or primary PCI. * Culprit vessels of left main or graft vessels. * Pregnant or nursing. * Others that investigators think should excluded.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Stemi - ST-segment elevation myocardial infarction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ST-elevation myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Stemi - ST-segment elevation myocardial infarction

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.